Farydak®
p (panobinostat) capsules

Farydak is the first histone deacetylase (HDAC) inhibitor approved to treat myeloma. Farydak is approved to treat myeloma in combination with Velcade® (bortezomib) and dexamethasone.

Who is a candidate for Farydak?
Farydak was approved by the US Food and Drug Administration (FDA) in combination with Velcade + dexamethasone for the treatment of patients with relapsed/refractory myeloma who have received at least two prior regimens.

How is Farydak given?
- Farydak is taken orally in capsule form.
- Farydak was approved at a starting dose of one 20-mg capsule taken on days 1, 3, 5, 8, 10, and 12 of a 3-week (21-day) treatment cycle. Farydak dosing can be thought of as “3-2-1” (3 times a week, 2 weeks on, 1 week off). Velcade and dexamethasone are given at their standard doses in combination.
- Dosing of Farydak, Velcade, and dexamethasone (FVD) can be modified to reduce side effects and enhance tolerance.
- The FVD regimen can be continued for up to 8 cycles, and may be continued after 8 cycles if the patient is benefiting from the therapy and is tolerating it.

What you should know before taking Farydak
- To avoid drug interactions, discuss all medications and supplements you are taking with your doctor or pharmacist.
- Do not eat grapefruit, star fruit, or pomegranate, or drink their juices while taking Farydak.

(continues on reverse side)
Swallow Farydak with a cup of water at about the same time of day each time you take it. Do not crush, break, or open the capsules.

If you miss a dose of Farydak, take it as soon as possible and up to 12 hours after your scheduled dose.

If you take too much Farydak, call your doctor.

What are the possible side effects of Farydak?
- Severe diarrhea
- Cardiac (heart) problems related to arrhythmias
- Low blood cell counts
- Bleeding (from low platelet count)
- Increased risk of infection
- Liver toxicity (hepatotoxicity)
- Fatigue
- Nausea and vomiting
- Peripheral edema
- Decreased appetite
- Fever

Are there special cautions with Farydak?
- Women of child-bearing potential should use effective birth control during treatment with Farydak and for 1 month after the last dose.
- Males who are sexually active should use condoms during treatment with Farydak and for 3 months after the last dose.
- Women who are breastfeeding should not take Farydak because it is not known if it will pass into the breast milk.

Farydak and patient resources
- Please visit oncologyaccessnow.com or call 800.282.7630 for more information.
- Regardless of insurance coverage, all patients have access to a free 21-day (one cycle) supply of Farydak capsules.
- A $0 co-pay program is available for eligible patients.
- Eligible patients may receive other types of financial support.
- Visit us.farydak.com to find a pharmacy that can dispense Farydak.

As always, the IMF urges you to discuss all medical issues with your doctor, and to contact the IMF with your myeloma questions and concerns.